Notable Thursday Option Activity: DKNG, WMT, AQST

Walmart (WMT) options traded 118,504 contracts today (~11.9M underlying shares), equal to about 61.2% of its one‑month average daily volume (19.4M shares), with notable concentration in the $90 put expiring Jan 16, 2026 (17,935 contracts, ~1.8M shares). Aquestive Therapeutics (AQST) saw 13,296 option contracts (~1.3M underlying shares, ~54.3% of its ADTV of 2.4M), led by the $11 call expiring Feb 20, 2026 (5,140 contracts, ~514k shares); these large relative flows suggest concentrated directional positioning or hedging interest but do not by themselves imply a change to fundamentals.

Analysis

Market structure: The concentrated WMT flow (17,935 Jan‑16‑2026 $90 puts ≈1.8M shares) signals heavy demand for long‑dated downside protection or large directional bearish bets; market‑makers and liquidity providers are the immediate beneficiaries via elevated IV and spread capture, while short‑tenor retail longs may face amplified intraday moves. AQST’s Feb‑20‑2026 $11 call block (5,140 contracts ≈514k shares) reads as speculative upside accumulation or sponsor-driven positioning in a small‑cap biotech; sector peers (XBI constituents) will see correlated vol repricing. Cross‑asset: expect modest lift in single‑stock implied vol (WMT, AQST), transient flow into equity financing and hedging that can slightly widen corporate credit spreads in retail names; macro FX and commodities impact is negligible.

Risk assessment: Tail risks include a pronounced consumer demand shock (worse‑than‑expected CPI or holiday sales) that would push WMT equity and retail peers down >10% in weeks, and an adverse clinical/regulatory outcome for AQST that could wipe out speculative premium. Immediate (days): higher realized vol and directional squeezes; short (weeks–months): option expiries and earnings/CPI will be decisive; long (quarters–years): secular retail share shifts and AQST binary outcomes dominate. Hidden dependencies: flows may be hedges for large stock positions, index rebalancing, or acquisition arbitrage — monitor 13F, block trades, and dark pool prints. Key catalysts: WMT quarterly sales/comp commentary, US retail data, CPI prints, and AQST trial/filing updates.

Trade implications: For WMT favor defined‑risk, income‑oriented entry: sell Jan‑16‑2026 $90/$85 put spreads (target credit ≥$1.00, position size 1–2% notional) to monetize elevated put demand while capping downside to ~5% width; alternatively, if worried about drawdown, buy Jan‑2026 $90 puts as 0.5–1% hedge. For AQST, take a selective long‑vol stance: buy Feb‑20‑2026 $11/$15 call verticals (limit cost to <$2.50, position 0.5–1%) or small outright call LEAP purchases if clinical catalysts are imminent. Pair idea: long AQST calls vs short XBI (size to neutralize beta) to isolate idiosyncratic upside.

Contrarian angles: The flow may be mostly hedging of existing long WMT exposure — heavy put buying can mask institutional accumulation, so shorting WMT outright risks being wrong if hedges expire worthless and stock rallies. AQST call concentration could be promotional or position building ahead of an M&A/filing; implied vol may be underpricing the binary risk — pay for defined‑risk structures rather than naked exposure. Monitor open interest change (≥20% day‑over‑day), dark‑pool print frequency, and SEC filings over the next 2–8 weeks to validate intent before scaling positions.

Key Decisions for Investors

• Establish a 1–2% notional bullish income trade in WMT: sell the Jan‑16‑2026 $90/$85 put spread (target credit ≥$1.00) to capture elevated put demand while limiting downside to the $85 strike; close or roll if WMT trades below $84 within 3 months.
• If you own WMT stock >1% weighting, add a 0.5–1% hedge by buying Jan‑2026 $90 puts (or equivalent collar) to cap downside through the Jan 2026 options expiry ahead of Q4 earnings and CPI windows.
• Speculative long in AQST: purchase Feb‑20‑2026 $11/$15 call verticals sized 0.5–1% of portfolio, limiting max loss to the premium (target cost <$2.50), and set a trailing stop to take profits at +50–100% or cut at −50%.
• Relative‑value pair: go long AQST call exposure vs short XBI futures/ETF sized to neutralize sector beta (initiate within 1–2 weeks); this isolates AQST idiosyncratic upside vs broad biotech drag from a negative trial environment.